Latest edition: 03 February 2026
Latest edition: 03 February 2026
The deal provides SanegeneBio with an upfront payment of $200m.
Aquestive plans a Type A FDA meeting and expects NDA resubmission in Q3 2026 after required studies.
Historically a steel production hub, Lehigh Valley will now help manufacture Lilly’s weight loss drug hopeful retatrutide.
Kyowa Kirin will file for rocatinlimab’s US approval, which was once Amgen’s most late-stage pipeline candidate.
The CHMP decision is based on Phase III AMPLITUDE study results in 696 mHSPC patients.
The programme will focus on accelerating treatments for rare diseases, most of which currently lack approved therapies.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
